Open access

NEWS - Hematology

Global Burden of Multiple Myeloma: A Systematic Analysis for the Global Burden of Disease Study 2016 – JAMA Oncology (free)

“Global incident cases of multiple myeloma more than doubled from 1990-2016 w/incident cases increasing by 126%. The largest increase was in middle-SDI countries, particularly E. Asia with a 262% increase in incidence cases”. (via @IHME_UW see Tweet)


Antifibrinolytics for heavy menstrual bleeding – Cochrane Library (link to abstract and summary)

“Antifibrinolytics appear effective tor treating for heavy menstrual bleeding, without substantially increasing the rate of adverse events” (via @CochraneLibrary see Tweet)


Clinical Practice Guideline: Iron Deficient Anemia – Toward Optimized Practice (TOP) (free PDF)

See also: Summary (free PDF)

Related: see all TOP Clinical Practice Guidelines, a practical resource for Family Physicians at the point of care.


Early Recurrence and Major Bleeding in Patients With Acute Ischemic Stroke and Atrial Fibrillation Treated With Non–Vitamin‐K Oral Anticoagulants (RAF‐NOACs) Study – Journal of the American Heart Association (free)

“Composite rates of recurrence and major bleeding were 12.4% in patients who initiated NOACs within 2 days after acute stroke, 2.1% in those who initiated NOACs between 3 and 14 days, and 9.1% in patients who initiated NOACs >14 days after acute stroke. Future randomized studies to assess timing of initiation and choice of agent in patients with acute stroke and AF are warranted”.


Association of Warfarin Use With Lower Overall Cancer Incidence Among Patients Older Than 50 Years – JAMA Internal Medicine (free)

“In this population-based cohort study of 1.256.725 persons, there was a significantly lower age- and sex-adjusted incidence rate ratio of cancer among warfarin users vs nonusers”.


Pregnancy, thrombophilia, and the risk of a first venous thrombosis: systematic review and bayesian meta-analysis – The BMJ (free)

“Women with antithrombin, protein C, or protein S deficiency or with homozygous factor V Leiden should be considered for antepartum or postpartum thrombosis prophylaxis, or both”.


FDA News Release: FDA approval brings first gene therapy to the United States (free)

Commentaries: A $475,000 cancer drug: Wall Street sees ‘bargain’; patients see ‘completely broken’ system – HealthNewsReview (free) FDA Approves First CAR-T Cell Therapy for Pediatric Acute Lymphoblastic Leukemia – National Institutes of Health (free) AND FDA Approves First Gene-Altering Leukemia Treatment, Costing $475.000 – New York Times (10 articles per month are free) AND The FDA Approves a Landmark Cancer Drug – The Atlantic (free)

“…is a cancer therapy that represents several things at once: a game-changing way to treat cancer through genetic engineering, a novel paradigm for the biotech business, and the latest turn in the debate over just how astronomically expensive a life-saving therapy can be”. (from The Atlantic)


Deferasirox for managing iron overload in people with thalassaemia – Cochrane Library (free)

Full review: Deferasirox for managing iron overload in people with thalassaemia – Cochrane Library (link to abstract – $ for full-text)

Iron chelation with oral Deferasirox (instead of injected deferoxamine) may offer an important treatment option for people with thalassaemia and secondary iron overload.


Venous Thromboembolism Prophylaxis in Major Orthopedic Surgery: Systematic Review Update. Comparative Effectiveness Review – Agency for Healthcare Research and Quality (free report and summary)

See also: Executive summary (free PDF)

Source: ACP Journal Wise ($ resource to find articles of interest)

Comprehensive review on the evidence regarding thromboembolism prophylaxis in major orthopedic surgery.


Direct oral anticoagulants for treatment of HIT: update of Hamilton experience and literature review – Blood (link to abstract – $ for full-text)

Source: Direct Oral Anticoagulants for Heparin-Induced Thrombocytopenia – Journal Watch ($)

This literature review and observational study suggest direct oral anticoagulants (rivaroxaban, apixaban, dabigatran) are safe and effective for the treatment of Heparin-induced Thrombocytopenia.


A Meta-analysis of the Impact of Aspirin, Clopidogrel, and Dual Antiplatelet Therapy on Bleeding Complications in Noncardiac Surgery – Annals of Surgery (link to abstract – $ for full-text)

Source: EvidenceAlerts (free resource to find articles of interest)

“Antiplatelet therapy at the time of noncardiac surgery confers minimal bleeding risk with no difference in thrombotic complications. In many cases, it is safe to continue antiplatelet therapy in patients with important indications for their use”


Nucleated red blood cells, critical illness survivors and postdischarge outcomes: a cohort study – Critical Care (free)

“Presence of nucleated RBCs is a robust predictor of post-discharge mortality and unplanned hospital readmission” (RT @Crit_Care see Tweet)


Non–Vitamin K Antagonist Oral Anticoagulant Dosing in Patients With Atrial Fibrillation and Renal Dysfunction – Journal of The American College of Cardiology (link to abstract – $ for full-text)

Commentary: NOAC Doses: Just Stick to the Label – MedPage Today (free registration required)

“Among the 1,473 patients with a renal indication for dose reduction, 43.0% were potentially overdosed, which was associated with a higher risk of major bleeding”


Effect of Low-Dose Ferrous Sulfate vs Iron Polysaccharide Complex on Hemoglobin Concentration in Young Children With Nutritional Iron-Deficiency Anemia: A Randomized Clinical Trial – JAMA (link to abstract – $ for full-text)

The JAMA Network – For the Media: Treating Nutritional Iron-Deficiency Anemia in Children (free)

Commentaries: Ferrous Sulfate Drops Tied to Higher Hemoglobin Increases in Kids with Anemia – Physician’s First Watch (free) AND Traditional treatment is better for iron-deficiency anaemia in children – OnMedica (free) AND Ferrous Sulfate Effective for Iron-Deficiency Anemia in Kids – Medscape (free registration required)

Researchers expected that Iron Polysaccharide Complex would restore hemoglobin more effectively, because it is designed to be tolerated better, but the proportion of infants and children with a complete resolution of iron-deficiency anemia was higher in the ferrous sulfate group (29 percent vs 6 percent).


Page 1 of 212

Stay updated in your specialty!

No spam, just news
Unsubscribe with one click